Expression of cell cycle inhibitors p21, p27, p14 and p16 in gliomas. Correlation with classic prognostic factors and patients' outcome

Neuropathology

Volumn 28, Issue 1, 2008, Pages 35-42

  Zolota, Vassiliki ^a,b   Tsamandas, Athanassios C ^a   Aroukatos, Panagiotis ^a   Panagiotopoulos, Vassilios ^a   Maraziotis, Theodore ^a   Poulos, Constantinos ^a   Scopa, Chrisoula D ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b NONE   (Greece)

Author keywords

Cell cycle proteins; Cell proliferation; Glioma; Immunohistochemistry; Prognosis

Indexed keywords

CELL CYCLE PROTEIN; KI 67 ANTIGEN; PROTEIN P14; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AGE; AGED; ARTICLE; ASTROCYTE; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 37549070721     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2007.00844.x     Document Type: Article

References (32)

1. Cavenee WK, Furnari FB, Nagane M et al. Diffusely infiltrating astrocytomas. In : Kleihues P, Cavenee WK, eds. Tumors of the Nervous System. Pathology and Genetics: World Health Organization International Classification of Tumours. Lyon : IARC Press, 2000 10.
2. Tortosa A, Vinolas N, Villa S et al. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 2003 97 : 1063 1071.
3. Louis DN, Gusella JF. A tiger dehind many doors: multiple genetic pathways to malignant glioma. Trends Genet 1995 11 : 412 415.
4. Collins VP. Genetic alterations in gliomas. J Neurooncol 1995 24 : 37 38.
5. Louis DN. A molecular genetic model of astrocytoma histopathology. Brain Pathol 1997 7 : 755 764.
6. Ohgaki H, Shauble B, zur Hausen A, von Ammon K, Kleihues P. Genetic alterations associated with the evolution and progression of astrocytic brain tumors. Virchows Arch 1995 427 : 113 118.
7. Reifenberger J, Ring G, Gies U et al. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 1996 55 : 822 831.
8. Watanabe K, Sato K, Biernat W et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 1997 4 : 523 540.
9. Delsal G, Loda M, Pagano M. Cell cycle and cancer: critical events at the G1 restriction point. Crit Rev Oncogenesis 1996 7 : 127 142.
10. Jung JM, Bruner J, Ruan S et al. Increased levels of p21WAF1/Cip1 in human brain tumors. Oncogene 1995 11 : 2021 2028.
11. Slingerland J, Pagano M. Regulation of the Cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000 183 : 10 17.
12. Cordon-Cardo C, Koff A, Drobnjak M et al. Distict altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostate carcinoma. J Natl Cancer Inst 1998 90 : 1284 1291.
13. Kirla RM, Haapasalo HK, Kalimo H, Salminen EK. Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer 2003 97 : 644 648.
14. Stott FJ, Bates S, James M et al. The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998 17 : 5001 5014.
15. Ivanchuk SM, Mondal S, Dirks PB, Rutka JT. The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth. J Neurooncol 2001 51 : 219 229.
16. Rosenblum MK, Bilbao JM, Ang LC. Neuromuscular system: central nervous system: glial tumors. In : Rosai J, ed. Rosai and Ackerman's Surgical Pathology. New York : Mosby, 2004 2461 2622.
17. Scopa CD, Tsamandas AC, Zolota V, Kalofonos HP, Batistatou A, Vagianos C. Potential role of bcl-2 and ki-67 expression and apoptosis in colorectal carcinoma: a clinicopathologic study. Dig Dis Sci 2003 48 : 1990 1997.
18. McKeever PE, Strawderman MS, Yamini B, Mikhail AA, Blaivas M. MIB-1 proliferation index predicts survival among patients with grade II astrocytoma. J Neuropathol Exp Neurol 1998 57 : 931 936.
19. Korshunov A, Golanov A, Sycheva R. Immunohistochemical markers for prognosis of anaplastic astrocytomas. J Neurooncol 2002 58 : 203 215.
20. Schiffer D, Cavalla P, Chio A, Richiardi P, Giordana MT. Proliferative activity and prognosis of low-grade astrocytomas. J Neurooncol 1997 34 : 31 35.
21. Perry A, Jenkins RB, O'Fallon JR et al. Clinicopathologic study of 85 similarly treated patients wth anaplastic astrocytic tumors. An analysis of DNA content (ploidy), cellular proliferation, and p53 expression. Cancer 1999 86 : 672 683.
22. Hilton D, Penney M, Evans B, Sanders H, Love S. Evaluation of Molecular Markers in Low-Grade Diffuse Astrocytomas. Am J Surg Path 2002 26 : 472 478.
23. Korkolopoulou P, Kouzelis K, Christodoulou P, Papanikolaou A, Thomas-Tsagli E. Expression of retinoblastoma gene product and p21 (WAF1/Cip1) protein in gliomas: correlations with proliferation markers, p53 expression and survival. Acta Neuropathol 1998 95 : 617 624.
24. Waf1/Cip1 in Protein Kinase C Alpha-Induced Cell Cycle Progression. Mol Cel Biol 2000 20 : 4580 4590.
25. Zagzag D, Blanco CY, Friedlander DR, Miller DC, Newcomb E. Expression of p27KIP1 in Human Gliomas. Relationship Between Tumor Grade, Proliferation Index, and Patient Survival. Hum Path 2003 34 : 48 53.
26. Fuse T, Tanikawa M, Nakanishi M et al. p27Kip1 expression by contact inhibition as a prognostic index of human glioma. J Neurochem 2000 74 : 1393 1399.
27. Nakasu S, Nakajima M, Handa J. Anomalous p27kip1 expression in a subset of malignant gliomas. Brain Tumor Pathol 1999 16 : 17 21.
28. ARF Silencing by Promoter Hypermethylation Mediates Abnormal Intracellular Localization of MDM2. Cancer Res 2001 61 : 2816 2821.
29. ARF Gene Deletion in High-grade Adult and Pediatric Astrocytomas. Hum Path 2000 31 : 115 119.
30. Ichimura K, Bondesson BM, Goike MH, Schmidt EE, Moshref A, Collins VP. Deregulation of the p14ARF/MDM2/p53 Pathway Is a Prerequisite for Human Astrocytic Gliomas with G1-S Transition Control Gene Abnormalities. Cancer Res 2000 60 : 417 424.
31. Ghimenti C, Fiano V, Chiado-Piat L, Chio A, Cavalla P, Schiffer D. Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets. J Neurooncol 2003 61 : 95 102.
32. Piva R, Cavalla P, Bortolotto S et al. CDKN2/p16 inactivation and p16 immunhistochemistry in astrocytic gliomas. Int J Oncol 1998 12 : 55 58.